Cao et al. examined the challenge of identifying HCC in patients with low AFP levels, particularly in relation to cirrhotic patients, and the prospective use of apyrimidinic endodeoxyribonuclease 1 (APEX1) in these instances [14]. This evidence concerns the gene AFP and hepatocellular carcinoma.